Semaglutide
A potent GLP-1 receptor agonist with proven efficacy in glycemic control and weight management, representing one of the most impactful metabolic peptides in clinical medicine.
Overview
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is a 31-amino acid peptide analog of native GLP-1 with key structural modifications—including an acyl side chain (C18 fatty diacid) and amino acid substitutions—that confer extended half-life via albumin binding and resistance to DPP-4 enzymatic degradation, enabling once-weekly subcutaneous dosing or once-daily oral administration.
Semaglutide has received FDA approval under multiple brand names: Ozempic (injectable, type 2 diabetes), Wegovy (injectable, chronic weight management), and Rybelsus (oral, type 2 diabetes). It has become one of the most studied and commercially successful peptide therapeutics, with landmark clinical trial programs (SUSTAIN, STEP, SELECT) demonstrating significant benefits for glycemic control, weight management, and cardiovascular risk reduction.
Mechanism of Action
Semaglutide acts as a potent agonist of the GLP-1 receptor, engaging multiple organ systems:
- Pancreatic Effects: Stimulates glucose-dependent insulin secretion from pancreatic beta cells while suppressing inappropriate glucagon release from alpha cells. This dual action improves glycemic control while maintaining low hypoglycemia risk.
- Central Appetite Regulation: Crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamus and brainstem, reducing appetite and promoting satiety. This central action is the primary driver of its weight loss effects.
- Gastric Emptying: Slows gastric emptying, contributing to reduced postprandial glucose excursions and enhanced satiety signals from the gastrointestinal tract.
- Cardiovascular Effects: Research indicates direct and indirect cardiovascular benefits, including improvements in endothelial function, reduction in inflammatory markers, and favorable effects on lipid profiles.
- Extended Pharmacokinetics: The C18 fatty diacid chain enables strong non-covalent binding to serum albumin, reducing renal clearance and providing a half-life of approximately 7 days—enabling once-weekly dosing.
Key Research Findings
- STEP Trials (Weight Management): The STEP clinical trial program demonstrated 14.9% to 17.4% body weight reduction with semaglutide 2.4mg weekly over 68 weeks, significantly surpassing previous pharmacological weight loss benchmarks.
- SUSTAIN Trials (Diabetes): Across the SUSTAIN program, semaglutide demonstrated superior HbA1c reduction compared to other GLP-1 RAs and insulin, with consistent weight loss benefits across diverse patient populations.
- SELECT Trial (Cardiovascular): The landmark SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide in overweight/obese individuals with established cardiovascular disease, independent of diabetes status.
- NASH/Liver Research: Studies have shown semaglutide significantly reduces hepatic steatosis and may promote resolution of non-alcoholic steatohepatitis (NASH) histological features.
- Oral Formulation: The successful development of oral semaglutide (Rybelsus) using the SNAC absorption enhancer represents a landmark in peptide drug delivery technology.
Research Applications
- Obesity and Weight Management Research: Investigating GLP-1 mediated appetite suppression and body composition changes.
- Type 2 Diabetes Research: Studying glucose-dependent insulin secretion, beta-cell preservation, and glycemic control.
- Cardiovascular Research: Exploring cardioprotective mechanisms and MACE risk reduction in metabolic populations.
- NAFLD/NASH Research: Investigating hepatoprotective effects and liver fat reduction.
- Peptide Drug Delivery: Studying the pharmacokinetics of acylated peptides and oral peptide delivery systems.
Dosing Protocols (Research Use Only)
The following dosing information reflects approved clinical protocols and research literature:
| Parameter | Details |
|---|---|
| Diabetes Dosing (Injectable) | 0.25 mg → 0.5 mg → 1 mg → 2 mg weekly (dose escalation) |
| Weight Management Dosing | 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg weekly |
| Oral Dosing | 3 mg → 7 mg → 14 mg daily (taken on empty stomach) |
| Escalation Period | 4 weeks per dose step (16 – 20 weeks to maintenance) |
| Route | Subcutaneous injection (weekly) or oral (daily) |
This profile is provided for educational and informational purposes only. Semaglutide is sold as a research chemical and is not approved by the FDA for human use. All information presented is based on published research literature and should not be construed as medical advice. Always consult qualified professionals before making any decisions related to peptide research.
Ready to Research Semaglutide?
Get ≥99% purity research-grade peptides with COA from Iron Peak Peptides.